TORONTO and HAIFA, Israel, Aug. 15, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”) is pleased to announce significant advancements in their manufacturing process of exosomes. Exosomes, which are naturally released by cells, hold immense promise for regenerative medicine and they
TORONTO and HAIFA, Israel, Aug. 09, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (the “Company” or “NurExone”) is pleased to announce new data for its ExoPTEN nanodrug, marking a significant step towards commercial-grade manufacturing. Building on the announcement of a new Good Manufacturing Practice
TORONTO and HAIFA, Israel, July 29, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company developing regenerative medicine therapies, is pleased to announce that the Israel Patent Office recently issued a Notice of Allowance for an ExoPTEN patent,
A pioneering biopharmaceutical company, is pleased to announce the preliminary results from a small-scale controlled study exploring the use of its flagship nanodrug, ExoPTEN, for optic nerve recovery in a rat model at Sheba Medical Center. This study marks a second clinical indication being investigated for ExoPTEN. The study was
TORONTO and HAIFA, Israel, July 05, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, is pleased to announce two significant updates aimed at advancing our mission and improving stakeholder engagement. Dr. Lior Shaltiel, Chief Executive Officer of
(OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, is pleased to announce a pre-clinical study to explore the potential of NurExone’s exosome-based therapies in regenerating damaged optic nerves. The study, initiated by renowned ophthalmologist and serial entrepreneur Prof. Michael Belkin from Tel Aviv University’s Goldschleger Eye
TORONTO and HAIFA, Israel, June 21, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, welcomes Dr. Yona Geffen, as a consultant, to support the Company’s preclinical and clinical activities. Dr. Geffen, who currently serves as Vice President
TORONTO and HAIFA, Israel, June 04, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company developing regenerative medicine therapies, is pleased to announce the voting results from its annual general and special meeting of shareholders (“Shareholders”) held on
NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company developing regenerative medicine therapies, is pleased to announce its financial and operational results for the three months ended March 31, 2024. On March 1, 2024, the Company commenced the setup of in-house laboratories
ORONTO and HAIFA, Israel, May 17, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, proudly welcomes Dr. Ram Petter, Ph.D., MBA, as a consultant, to assist in driving the Company’s strategic collaborations. With a distinguished background in
